Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis

What Was Tested

The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a clinical trial, phase ii.

To determine the durability of this effect, an observation year (BES Year 2) off therapy was planned.

Why It Was Studied

In premenopausal IOP, BMD gains on teriparatide-denosumab were maintained on bisphosphonate over 1 year.

In premenopausal IOP, the optimal duration of bisphosphonate after denosumab requires further study.

Who Took Part

The abstract describes 19 women taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

19 women, aged 44 ± 8, with premenopausal IOP.

How the Study Was Run

BMD by DXA, serum CTX every 6 months (M).

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Collagen Type I and Denosumab.

The authors tagged it with the keywords Alendronate, Bisphosphonate, Bone turnover markers, Denosumab cessation, Premenopausal osteoporosis and Teriparatide.

What This Means in Plain Language

This is a clinical trial, phase ii of Teriparatide in 19 women in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.